Headless WordPress - PROD

Strategic approaches to CAR T-cell and bispecific antibody therapy utilization in relapsed/refractory disease

https://www.sharecare.com/hcp/cancer/cellular-immunotherapy-multiple-myeloma-patient-selection

Patient selection for cellular immunotherapies in multiple myeloma: Identifying optimal candidates and managing the pre-treatment interval

Decoding patient eligibility and expanding CAR T-cell therapy potential

https://www.sharecare.com/hcp/cancer/car-tcell-therapy-candidate-selection-sines-outcomes

|Breaking barriers to access in treating multiple myeloma

CAR T-cell therapy candidate selection and the role of SINEs in enhancing outcomes

Addressing disparities in care for improved outcomes

https://www.sharecare.com/hcp/cancer/breaking-barriers-treating-multiple-myeloma

Breaking barriers to access in treating multiple myeloma||

Breaking barriers to access in treating multiple myeloma

Exploring advancements in immunotherapies and targeted strategies for hematologic malignancies

https://www.sharecare.com/hcp/cancer/cutting-edge-innovations-multiple-myeloma

||Breaking barriers to access in treating multiple myeloma|Breaking barriers to access in treating multiple myeloma||

Cutting-edge innovations in multiple myeloma: A new era of treatment

Featured Content

Dx Dialogues: Multiple Myeloma

In these videos, hematologist and medical oncologist Dr. Sborov discusses key considerations in advancing myeloma therapy, including identifying patients for combination therapies incorporating CAR-T cell therapy, exploring versatile treatment approaches for refractory disease, and examining strategies to optimize long-term outcomes following anti-CD38 therapy. He also highlights novel strategies to overcome resistance and delves into emerging therapeutic options that are shaping the future of myeloma treatment.